GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator

Neuropharmacology

Volumn 49, Issue 7, 2005, Pages 1077-1087

  Moskal, Joseph R ^a   Kuo, Amy G ^b   Weiss, Craig ^b   Wood, Paul L ^a,c   O'Connor Hanson, Amy ^d   Kelso, Stephen ^d   Harris, Robert B ^e   Disterhoft, John F ^b  

^a Northwestern University   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Nyxis Neurotherapies Inc   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Commonwealth Biotechnologies Inc ^*  (United States)

Author keywords

Glycine; Hippocampus; Monoclonal antibody; N methyl D aspartate receptor; Partial agonist; Peptide

Indexed keywords

GLYCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GLYX 13; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; TETRAPEPTIDE AMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COGNITION; CONDITIONING; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EYELID REFLEX; HIPPOCAMPUS; LEARNING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; CEREBELLUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COGNITION; CONDITIONING, EYELID; CYCLOSERINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; MEMBRANE POTENTIALS; OLIGOPEPTIDES; PATCH-CLAMP TECHNIQUES; RATS; RATS, INBRED BN; RATS, INBRED F344; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; XENOPUS LAEVIS;

EID: 27144543724     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2005.06.006     Document Type: Article

References (72)

1. J.W. Allen A review of the actions of d-cycloserine, a putative nootropic agent, at the NMDA receptor complex-associated glycine binding site McGill J. Med. 2 1996 40 50
2. M.W. Bradbury, C.S. Patlak, and W.H. Oldendorf Analysis of brain uptake and loss of radiotracers after intracarotid injection Am. J. Physiol. 299 1975 1110 1115
3. A.L. Buller, H.C. Larson, B.E. Schneider, J.A. Beaton, R.A. Morrisett, and D.T. Monaghan The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition J. Neurosci. 14 1994 5471 5484
4. G.L. Collingridge, S.J. Kehl, and H.J. McLennan Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus J. Physiol. 334 1983 33 46
5. M. Corsi, P. Fina, and D.G. Trist Co-agonism in drug-receptor interaction: illustrated by the NMDA receptors Trends Pharmacol. Sci. 17 1996 220 222
6. A.H. Dickenson, and E. Aydar Antagonism at the glycine site on the NMDA receptor reduces spinal nociception in the rat Neurosci. Lett. 121 1991 263 266
7. H.C. Diener, A. Alkhedr, O. Busse, W. Hacke, P.H. Zingmark, N. Jonsson, H. Basun Study group Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability limit study J. Neurol. 249 2002 561 568
8. J.F. Disterhoft, and M.M. Oh Modulation of cholinergic transmission enhances excitability of hippocampal pyramidal neurons and ameliorates learning impairments in aging animals Neurobiol. Learn. Mem. 80 2003 223 233
9. W.C. Dougall, N.C. Peterson, and M.I. Greene Antibody-structure-based design of pharmacological agents Trends Biotechnol. 12 1994 372 379
10. M.R. Emmett, S.J. Mick, J.A. Cler, T.S. Rao, S. Iyengar, and P.L. Wood Actions of d-cycloserine at the N-methyl-d-aspartate-associated glycine receptor site in vivo Neuropharmacology 30 1991 1167 1171
11. A.E. Evins, E. Amico, T.A. Posever, R. Toker, and D.C. Goff d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia Schizophr. Res. 56 2002 19 23
12. J.E. Finkelstein, J.M. Hengemihle, D.K. Ingram, and H.L. Petri Milacemide treatment in mice enhances acquisition of a Morris-type water maze task Pharmacol. Biochem. Behav. 49 1994 707 710
13. J.F. Flood, F.E. Morley, and T.H. Lanthorn Effect on memory processing by d-cycloserine, an agonist of the NMDA/glycine receptor Eur. J. Pharmacol. 221 1992 249 254
14. G.E. Handelmann, M.E. Nevins, L.L. Muellers, S.M. Arnolde, and A.A. Cordi Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents Pharmacol. Biochem. Behav. 34 1989 823 828
15. R. Haring, P.K. Stanton, M. Scheideler, and J.R. Moskal Glycine-like modulation of N-methyl-d-aspartate receptors by a monoclonal antibody that enhances long-term potentiation J. Neurochem. 57 1991 323 332
16. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D.C. Javitt Placebo-controlled trail of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia Am. J. Psychiatry 159 2002 480 482
17. R.L. Herting Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia Ann. N.Y. Acad. Sci. 640 1991 237 240
18. M. Hollmann Ionotropic glutamate receptors in the CNS P. Jonas H. Monyer Handbook of Experimental Pharmacology vol. 141 1999 Springer Berlin 1 98
19. M. Hollmann, and S. Heinemann Cloned glutamate receptors Ann. Rev. Neurosci. 17 1994 31 108
20. M. Honer, D. Benke, B. Laube, J. Juhse, R. Keckendorn, H. Allgeiers, C. Angst, H. Monyer, P.H. Seeburg, H. Betz, and H. Mohler Differentiation of glycine antagonist sites of N-methyl-d-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors J. Biol. Chem. 273 1998 11158 11163
21. W.F. Hood, R.P. Compton, and J.B. Monahan d-Cycloserine: a ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics Neurosci. Lett. 98 1989 91 95
22. R.A. Houghten, C. Pinilla, S.E. Blondelle, J.R. Appel, C.T. Dooley, and J.H. Cuervo Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery Nature 354 1991 84 86
23. J.W. Johnson, and P. Ascher Glycine potentiates the NMDA response in cultured mouse brain neurons Nature 325 1987 529 531
24. J.A. Kemp, A.C. Foster, P.D. Leeson, T. Priestley, R. Tridgett, L.L. Iversen, and G.N. Woodruff 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-d-aspartate receptor complex Proc. Natl Acad. Sci. U.S.A. 85 1988 6547 6550
25. J.M. Laird, G.S. Mason, J. Webb, R.G. Hill, and R.J. Hargraves Effects of a partial agonist and a full antagonist acting at the glycine site of the NMDA receptor on inflammation-induced mechanical hyperalgesia in rats Br. J. Pharmacol. 117 1996 1487 1492
26. J.P. Leonard, and S.R. Kelso Apparent desensitization of NMDA responses in Xenopus oocytes involves calcium-dependent chloride current Neuron 4 1990 53 60
27. J.C. Marvizon, A. Lewin, and P. Skolnick 1-Aminocyclopropane carboxylic acid: a potent and selective ligand for the glycine modulatory site of the N-methyl-d-aspartate receptor complex J. Neurochem. 52 1989 992 994
28. R.D. Mayforth Designing Antibodies 1993 Academic Press San Diego pp. 1-48
29. H. Meguro, H. Mori, K. Araki, E. Kushiya, T. Kutsuwada, M. Yamazaki, T. Kumanishi, M. Arakawa, K. Sakimura, and M. Mishina Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs Nature 357 1992 70 74
30. D.T. Monaghan, H.J. Olverman, L. Nguyen, J.C. Watkins, and C.W. Cotman Two classes of N-methyl-d-aspartate recognition sites: differential distribution and differential regulation by glycine Proc. Natl Acad. Sci. U.S.A. 85 1988 9836 9840
31. G.F. Morris, R. Bullock, S.B. Marshall, A. Marmarou, A. Maas, and L.F. Marshall Failure of the competitive N-methyl-d-aspartate antagonist Selfotel (CGS 19755) in the treatment of sever head injury: results of two phase III clinical trials. The Selfotel investigators J. Neurosurg. 91 1999 737 743
32. R.G. Morris, E. Anderson, G.S. Lynch, and M. Baudry Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist Nature 319 1986 774 776
33. J.R. Moskal, and A.E. Schaffner Monoclonal antibodies to the dentate gyrus: immunocytochemical characterization and flow cytometric analysis of hippocampal neurons bearing a unique cell-surface antigen J. Neurosci. 6 1986 2045 2053
34. J.R. Moskal, H. Yamamoto, and P.A. Colley The use of antibody engineering to create novel drugs that target N-methyl-d-aspartate receptors Curr. Drug Targets 2 2001 331 345
35. J.R. Moskal, P.E. Potter, P.K. Rauschkolb, R. Sibson, T. Beach, and C.J. Kovelowski The NMDA receptor, glycine-site partial agonist, NT-13, is neuroprotective using a gerbil model of ischemia Soc. Neurosci. Abs. 2002 Prog. No. 202.8
36. 3H]-CGS 19755: a novel N-methyl-d-aspartate antagonist with nanomolar affinity in rat brain Br. J. Pharmacol. 95 1988 932 938
37. J.F. Murphy, and J.L. McGregor A peptide (P2) derived from the variable heavy chain of an anti-selectin monoclonal antibody (LYP20) inhibits leucocyte adhesion to thrombin-activated platelets and endothelial cells Br. J. Haematol. 120 2003 605 610
38. R.J. O'Brien, L.F. Lau, and R.L. Huganir Molecular mechanisms of glutamate receptor clustering at excitatory synapses Curr. Opin. Neurobiol. 8 1988 364 369
39. W.H. Oldendorf Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard Brain Res. 24 1970 372 376
40. G.C. Palmer, R.J. Murray, C.L. Cramer, M.L. Stagnitto, M.K. Knowles, L.R. Freedman, M.S. Eismann, N. Mahmood, M. Balestra, A.R. Borrelli, T.J. Hudzik, and D.J. McCarthy [S]-AR-R 15896AR - a novel anticonvulsant: acute safety, pharmacokinetic and pharmacodynamic properties J. Pharmacol. Exp. Ther. 288 1999 121 132
41. F. Perosa, G. Luccarelli, M. Prete, E. Favoino, D. Ferrone, and F. Dammacco Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide J. Immunol. 15 2003 1918 1926
42. T. Priestley, A.L. Horne, R.M. McKernana, and J.A. Kemp The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures Brain Res. 531 1990 183 188
43. T. Priestley, G.R. Marshall, R.G. Hill, and J.A. Kemp L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective Br. J. Pharmacol. 124 1998 1767 1773
44. M. Quartaroli, N. Fasdelli, L. Gettelini, G. Maraia, and M. Corsi GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice Eur. J. Pharmacol. 430 2001 219 227
45. D. Quartermain, T. Nuygen, J. Sheu, and R.L. Herting Milacemide enhances memory storage and alleviates spontaneous forgetting in mice Pharmacol. Biochem. Behav. 39 1991 31 35
46. D. Quartermain, J. Mower, M.F. Rafferty, R.L. Herting, and T.H. Lanthorn Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention Eur. J. Pharmacol. 257 1994 7 12
47. W. Qin, J. Feng, W. Zhang, Y. Li, and B. Shen A novel TNFα antagonizing peptide-Fc fusion protein designed based on the CDRs of TNFα neutralizing monoclonal antibody Biochem. Biophys. Res. Commun. 332 2004 1024 1028
48. M. Rigby, B. Le bourdelles, R.P. Heavens, S. Kelly, D. Smith, A. Butler, R. Hammans, J.H. Xueereb, P.J. Whiting, and I. Sirinathsinghji The messenger RNAs for the N-methyl-d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain Neuroscience 73 1996 429 447
49. G.S. Robinson, G.B. Crooks, P.G. Shinkman, and M. Gallagher Behavioral effects of MK-801 mimic deficits associated with hippocampal damage Psychobiology 17 1989 156 164
50. P.K. Stanton, J.M. Sarvey, and J.R. Moskal Inhibition of the production and maintenance of long-term potentiation in rat hippocampal slices by a monoclonal antibody Proc. Natl Acad. Sci. U.S.A. 84 1987 1684 1688
51. F.L. Strand Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders Prog. Drug Res. 61 2003 1 37
52. G.M. Schuster, and W.J. Schmidt d-Cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task Eur. J. Pharmacol. 224 1992 97 98
53. B.L. Schwartz, S. Hashtroudi, R.L. Herting, H. Handerson, and S.I. Deutsch Glycine prodrug facilitates memory retrieval in humans Neurology 41 1991 1341 1343
54. B.L. Schwartz, S. Hashtroudi, R.L. Herting, and S.I. Deutsch The effects of milacemide on item and source memory Clin. Neuropharmacol 15 1992 114 119
55. T. Tatlisumak, K. Takano, M.R. Meiler, and M. Fisher A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion Acta Neurochir. Suppl. 76 2000 331 333
56. L.T. Thompson, and J.F. Disterhoft Age- and dose-dependent facilitation of associative eyeblink conditioning by d-cycloserine Behav. Neurosci. 111 1997 1303 1312
57. L.T. Thompson, J.R. Moskal, and J.F. Disterhoft Hippocampus-dependent learning facilitated by a monoclonal antibody or d-cycloserine Nature 359 1992 638 641
58. G. Tribbick Multipin peptide libraries for antibody and receptor epitope screening and characterization J. Immunol. Methods 267 2002 27 35
59. M.D. Tricklebank, L.J. Bristow, P.H. Hutson, P.D. Leeson, M. Rowley, K. Saywell, L. Singh, F.D. Tattersall, L. Thorn, and B.J. Williams The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-d-aspartate (NMDA) receptor complex Br. J. Pharmacol. 113 1994 729 736
60. G.E. Tsai, W.E. Falk, J. Gunther, and J.T. Coyle Improved cognition in Alzheimer's disease with short-term d-cycloserine treatment Am. J. Psychiatry 156 1999 467 469
61. H.J. Tuominen, J. Tiihonen, and K. Wahlbeck Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis Schizophr. Res. 72 2005 225 234
62. R.E. Twyman, L.C. Gahring, J. Speiss, and S.W. Rogers Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site Neuron 14 1995 755 762
63. D.L. Walker, K.J. Ressler, K.T. Lu, and M. Davis Facilitation of conditioned fear extinction by systemic administration of intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats J. Neurosci. 22 2002 2343 2351
64. E.S. Ward, D. Gussow, A.D. Griffiths, P.T. Jones, and G. Winter Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli Nature 341 1989 484 485
65. C. Weiss, H. Bouwmeester, J.M. Power, and J.F. Disterhoft Hippocampal lesions prevent trace eyeblink conditioning in the freely moving rat Behav. Brain Res. 99 1999 123 132
66. C. Weiss, M.G. Knuttinen, J.M. Power, R.I. Patel, M.S. O'Connor, and J.F. Disterhoft Trace eyeblink conditioning in the freely moving rat: optimizing the conditioning parameters Behav. Neurosci. 113 1999 1100 1105
67. C. Weiss, A.R. Preston, M.M. Oh, R.D. Schwarz, D. Welty, and J.F. Disterhoft The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons J. Neurosci. 20 2000 783 790
68. A. Wenzel, J.M. Fritschy, H. Mohler, and D. Benke NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins J. Neurochem. 68 1997 469 478
69. P.L. Wood, M.R. Emmett, T.S. Rao, S. Mick, J. Cler, and S. Iyengar In vivo modulation of the N-methyl-d-aspartate receptor complex by d-serine: potentiation of ongoing neuronal activity as evidenced by increased cerebellar cyclic GMP J. Neurochem 53 1989 979 981
70. P.L. Wood The NMDA receptor complex: a long and winding road to therapeutics IDrugs 8 2005 229 235
71. M. Yamazaki, H. Mori, K. Araki, K.J. Mori, and M. Mishina Cloning, expression and modulation of a mouse NMDA receptor subunit FEBS Lett. 300 1992 39 45
72. G.C. Yeh, D.W. Bonhaus, J.V. Nadler, and J.O. McNamara N-methyl-d-aspartate receptor plasticity in kindling: quantitative and qualitative alterations in the N-methyl-d-aspartate receptor-channel complex Proc. Natl Acad. Sci. U.S.A. 86 1989 8157 8160